;PMID: 9537203
;source_file_1306.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:43..165] = [t:43..165]
;2)section:[e:169..281] = [t:169..281]
;3)section:[e:285..325] = [t:285..325]
;4)sentence:[e:329..544] = [t:329..544]
;5)sentence:[e:545..691] = [t:545..691]
;6)sentence:[e:692..761] = [t:692..761]
;7)sentence:[e:762..844] = [t:762..844]
;8)sentence:[e:845..938] = [t:845..938]
;9)sentence:[e:939..1030] = [t:939..1030]
;10)sentence:[e:1031..1297] = [t:1031..1297]
;11)sentence:[e:1298..1362] = [t:1298..1362]
;12)sentence:[e:1363..1537] = [t:1363..1537]
;13)section:[e:1541..1585] = [t:1541..1585]

;section 0 Span:0..38
;Am J Clin Oncol  1998 Apr;21(2):155-60
(SEC
  (FRAG (NNP:[0..2] Am) (NNP:[3..4] J) (NNP:[5..9] Clin) (NNP:[10..15] Oncol)
        (CD:[17..21] 1998) (.:[22..29] Apr;21-LRB-) (CD:[29..30] 2)
        (-RRB-:[30..31] -RRB-) (CD:[31..35] :155) (CD:[35..38] -60)))

;sentence 1 Span:43..165
;Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2
;oncoprotein  expression in adenocarcinoma of the lung.
;[63..68]:gene-rna:"K-ras"
;[80..83]:gene-protein:"ras"
;[101..110]:gene-protein:"c-erb B-2"
;[138..164]:malignancy-type:"adenocarcinoma of the lung"
(SENT
  (NP-HLN
    (NP (JJ:[43..53] Prognostic) (NN:[54..59] value))
    (PP (IN:[60..62] of)
      (NP
        (NP (NN:[63..68] K-ras) (NNS:[69..78] mutations))
        (,:[78..79] ,)
        (NP (NN:[80..83] ras) (NN:[84..95] oncoprotein))
        (,:[95..96] ,) (CC:[97..100] and)
        (NP
          (NML (NN:[101..106] c-erb) (NN:[107..110] B-2))
          (NN:[111..122] oncoprotein) (NN:[124..134] expression))))
    (PP (IN:[135..137] in)
      (NP
        (NP (NN:[138..152] adenocarcinoma))
        (PP (IN:[153..155] of)
          (NP (DT:[156..159] the) (NN:[160..164] lung)))))
    (.:[164..165] .)))

;section 2 Span:169..281
;Nemunaitis J, Klemow S, Tong A, Courtney A, Johnston W, Mack M, Taylor W,
;Solano  M, Stone M, Mallams J, Mues G.
(SEC
  (FRAG (NNP:[169..179] Nemunaitis) (NNP:[180..182] J,) (NNP:[183..189] Klemow)
        (NNP:[190..191] S) (,:[191..192] ,) (NNP:[193..197] Tong)
        (NNP:[198..199] A) (,:[199..200] ,) (NNP:[201..209] Courtney)
        (NNP:[210..211] A) (,:[211..212] ,) (NNP:[213..221] Johnston)
        (NNP:[222..223] W) (,:[223..224] ,) (NNP:[225..229] Mack)
        (NNP:[230..232] M,) (NNP:[233..239] Taylor) (NNP:[240..241] W)
        (,:[241..242] ,) (NNP:[243..249] Solano) (NNP:[251..253] M,)
        (NNP:[254..259] Stone) (NNP:[260..262] M,) (NNP:[263..270] Mallams)
        (NNP:[271..273] J,) (NNP:[274..278] Mues) (NNP:[279..281] G.)))

;section 3 Span:285..325
;Texas Oncology, P.A., Dallas 75246, USA.
(SEC
  (FRAG (NNP:[285..290] Texas) (NNP:[291..299] Oncology) (,:[299..300] ,)
        (NNP:[301..305] P.A.) (,:[305..306] ,) (NNP:[307..313] Dallas)
        (CD:[314..319] 75246) (,:[319..320] ,) (NNP:[321..324] USA)
        (.:[324..325] .)))

;sentence 4 Span:329..544
;This trial was undertaken to determine the prognostic role of K-ras (p21),
;c-erb  B-2 (p185) protein expression, and the presence or nonpresence of a
;K-ras gene  mutation in patients with adenocarcinoma of the lung.
;[391..396]:gene-protein:"K-ras"
;[398..401]:gene-protein:"p21"
;[404..414]:gene-protein:"c-erb  B-2"
;[416..420]:gene-protein:"p185"
;[479..484]:gene-rna:"K-ras"
;[517..543]:malignancy-type:"adenocarcinoma of the lung"
(SENT
  (S
    (NP-SBJ-1 (DT:[329..333] This) (NN:[334..339] trial))
    (VP (VBD:[340..343] was)
      (VP (VBN:[344..354] undertaken)
        (NP-1 (-NONE-:[354..354] *))
        (S-PRP
          (NP-SBJ (-NONE-:[354..354] *))
          (VP (TO:[355..357] to)
            (VP (VB:[358..367] determine)
              (NP
                (NP (DT:[368..371] the) (JJ:[372..382] prognostic)
                    (NN:[383..387] role))
                (PP (IN:[388..390] of)
                  (NP
                    (NP (NN:[391..396] K-ras)
                      (PRN (-LRB-:[397..398] -LRB-)
                        (NP (NN:[398..401] p21))
                        (-RRB-:[401..402] -RRB-)))
                    (,:[402..403] ,)
                    (NP
                      (NML
                         (NN:[404..409] c-erb) (NN:[411..414] B-2)
                        (NML (-LRB-:[415..416] -LRB-) (NN:[416..420] p185)
                             (-RRB-:[420..421] -RRB-)))
                      (NN:[422..429] protein) (NN:[430..440] expression))
                    (,:[440..441] ,) (CC:[442..445] and)
                    (NP
                      (NP (DT:[446..449] the) (NN:[450..458] presence)
                          (CC:[459..461] or) (NN:[462..473] nonpresence))
                      (PP (IN:[474..476] of)
                        (NP (DT:[477..478] a) (NN:[479..484] K-ras)
                            (NN:[485..489] gene) (NN:[491..499] mutation))))))
                (PP-LOC (IN:[500..502] in)
                  (NP
                    (NP (NNS:[503..511] patients))
                    (PP (IN:[512..516] with)
                      (NP
                        (NP (NN:[517..531] adenocarcinoma))
                        (PP (IN:[532..534] of)
                          (NP (DT:[535..538] the) (NN:[539..543] lung)))))))))))))
    (.:[543..544] .)))

;sentence 5 Span:545..691
;This was a retrospective  study of 103 patients with adeno- or large-cell
;carcinoma of the lung who had  available paraffin-stored tumor material.
;[598..604]...[614..640]:malignancy-type:"adeno-"..."cell carcinoma of the
;lung"
;[608..640]:malignancy-type:"large-cell carcinoma of the lung"
(SENT
  (S
    (NP-SBJ (DT:[545..549] This))
    (VP (VBD:[550..553] was)
      (NP-PRD
        (NP (DT:[554..555] a) (JJ:[556..569] retrospective)
            (NN:[571..576] study))
        (PP (IN:[577..579] of)
          (NP
            (NP
              (NP (CD:[580..583] 103) (NNS:[584..592] patients))
              (PP (IN:[593..597] with)
                (NP
                  (NP
                    (NP (AFX:[598..603] adeno) (HYPH:[603..604] -)
                      (NML-1 (-NONE-:[604..604] *P*)))
                    (CC:[605..607] or)
                    (NP
                      (NML (JJ:[608..613] large) (HYPH:[613..614] -)
                           (NN:[614..618] cell))
                      (NML-1 (NN:[619..628] carcinoma))))
                  (PP (IN:[629..631] of)
                    (NP (DT:[632..635] the) (NN:[636..640] lung))))))
            (SBAR
              (WHNP-2 (WP:[641..644] who))
              (S
                (NP-SBJ-2 (-NONE-:[644..644] *T*))
                (VP (VBD:[645..648] had)
                  (NP (JJ:[650..659] available)
                    (ADJP (NN:[660..668] paraffin) (HYPH:[668..669] -)
                          (VBN:[669..675] stored))
                    (NN:[676..681] tumor) (NN:[682..690] material)))))))))
    (.:[690..691] .)))

;sentence 6 Span:692..761
;The relation of several clinical  variables to survival was analyzed.
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[692..695] The) (NN:[696..704] relation))
      (PP (IN:[705..707] of)
        (NP (JJ:[708..715] several) (JJ:[716..724] clinical)
            (NNS:[726..735] variables)))
      (PP (TO:[736..738] to)
        (NP (NN:[739..747] survival))))
    (VP (VBD:[748..751] was)
      (VP (VBN:[752..760] analyzed)
        (NP-1 (-NONE-:[760..760] *))))
    (.:[760..761] .)))

;sentence 7 Span:762..844
;Immunohistochemical techniques were used to  determine expression of p21 and
;p185.
;[831..834]:gene-protein:"p21"
;[839..843]:gene-protein:"p185"
(SENT
  (S
    (NP-SBJ-1 (JJ:[762..781] Immunohistochemical) (NNS:[782..792] techniques))
    (VP (VBD:[793..797] were)
      (VP (VBN:[798..802] used)
        (NP-1 (-NONE-:[802..802] *))
        (S-PRP
          (NP-SBJ (-NONE-:[802..802] *))
          (VP (TO:[803..805] to)
            (VP (VB:[807..816] determine)
              (NP
                (NP (NN:[817..827] expression))
                (PP (IN:[828..830] of)
                  (NP
                    (NP (NN:[831..834] p21))
                    (CC:[835..838] and)
                    (NP (NN:[839..843] p185))))))))))
    (.:[843..844] .)))

;sentence 8 Span:845..938
;Polymerase chain reaction (PCR) and  sequencing were used to determine K-ras
;mutation status.
;[845..855]:gene-protein:"Polymerase"
;[916..921]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP (NN:[845..855] Polymerase) (NN:[856..861] chain)
            (NN:[862..870] reaction))
        (NP (-LRB-:[871..872] -LRB-) (NN:[872..875] PCR)
            (-RRB-:[875..876] -RRB-)))
      (CC:[877..880] and)
      (NP (NN:[882..892] sequencing)))
    (VP (VBD:[893..897] were)
      (VP (VBN:[898..902] used)
        (NP-1 (-NONE-:[902..902] *))
        (S-PRP
          (NP-SBJ (-NONE-:[902..902] *))
          (VP (TO:[903..905] to)
            (VP (VB:[906..915] determine)
              (NP (NN:[916..921] K-ras) (NN:[922..930] mutation)
                  (NN:[931..937] status)))))))
    (.:[937..938] .)))

;sentence 9 Span:939..1030
;Tumor stage was the  only nonmolecular clinical variable predictive of
;survival (p=0.0001).
(SENT
  (S
    (NP-SBJ (NN:[939..944] Tumor) (NN:[945..950] stage))
    (VP (VBD:[951..954] was)
      (NP-PRD
        (NP (DT:[955..958] the) (JJ:[960..964] only)
            (JJ:[965..977] nonmolecular) (JJ:[978..986] clinical)
            (NN:[987..995] variable))
        (ADJP (JJ:[996..1006] predictive)
          (PP (IN:[1007..1009] of)
            (NP (NN:[1010..1018] survival)))
          (PRN (-LRB-:[1019..1020] -LRB-)
            (S
              (NP-SBJ (NN:[1020..1021] p))
              (VP (SYM:[1021..1022] =)
                (NP (CD:[1022..1028] 0.0001))))
            (-RRB-:[1028..1029] -RRB-)))))
    (.:[1029..1030] .)))

;sentence 10 Span:1031..1297
;A  combination of K-ras mutation and p 185 expression (p=0.0144), ras
;mutation and  strong p21 expression (p=0.0137), and K-ras mutation and the
;combined expression  of p21 and p185 were predictive of poor survival
;(p=0.0415) in univariate  analysis of all patients.
;[1049..1054]:gene-rna:"K-ras"
;[1068..1073]:gene-protein:"p 185"
;[1097..1100]:gene-rna:"ras"
;[1122..1125]:gene-protein:"p21"
;[1153..1158]:gene-rna:"K-ras"
;[1200..1203]:gene-protein:"p21"
;[1208..1212]:gene-protein:"p185"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1031..1032] A) (NN:[1034..1045] combination))
      (PP (IN:[1046..1048] of)
        (NP
          (NP
            (NP (NN:[1049..1054] K-ras) (NN:[1055..1063] mutation))
            (CC:[1064..1067] and)
            (NP
              (NML (NN:[1068..1069] p) (CD:[1070..1073] 185))
              (NN:[1074..1084] expression))
            (PRN (-LRB-:[1085..1086] -LRB-)
              (S
                (NP-SBJ (NN:[1086..1087] p))
                (VP (SYM:[1087..1088] =)
                  (NP (CD:[1088..1094] 0.0144))))
              (-RRB-:[1094..1095] -RRB-)))
          (,:[1095..1096] ,)
          (NP
            (NP (NN:[1097..1100] ras) (NN:[1101..1109] mutation))
            (CC:[1110..1113] and)
            (NP (JJ:[1115..1121] strong) (NN:[1122..1125] p21)
                (NN:[1126..1136] expression))
            (PRN (-LRB-:[1137..1138] -LRB-)
              (S
                (NP-SBJ (NN:[1138..1139] p))
                (VP (SYM:[1139..1140] =)
                  (NP (CD:[1140..1146] 0.0137))))
              (-RRB-:[1146..1147] -RRB-)))
          (,:[1147..1148] ,) (CC:[1149..1152] and)
          (NP
            (NP (NN:[1153..1158] K-ras) (NN:[1159..1167] mutation))
            (CC:[1168..1171] and)
            (NP
              (NP (DT:[1172..1175] the) (VBN:[1176..1184] combined)
                  (NN:[1185..1195] expression))
              (PP (IN:[1197..1199] of)
                (NP
                  (NP (NN:[1200..1203] p21))
                  (CC:[1204..1207] and)
                  (NP (NN:[1208..1212] p185)))))))))
    (VP (VBD:[1213..1217] were)
      (ADJP-PRD (JJ:[1218..1228] predictive)
        (PP (IN:[1229..1231] of)
          (NP (JJ:[1232..1236] poor) (NN:[1237..1245] survival)))
        (PRN (-LRB-:[1246..1247] -LRB-)
          (S
            (NP-SBJ (NN:[1247..1248] p))
            (VP (SYM:[1248..1249] =)
              (NP (CD:[1249..1255] 0.0415))))
          (-RRB-:[1255..1256] -RRB-)))
      (PP (IN:[1257..1259] in)
        (NP
          (NP (JJ:[1260..1270] univariate) (NN:[1272..1280] analysis))
          (PP (IN:[1281..1283] of)
            (NP (DT:[1284..1287] all) (NNS:[1288..1296] patients))))))
    (.:[1296..1297] .)))

;sentence 11 Span:1298..1362
;The sole presence of K-ras mutation was predictive of  survival.
;[1319..1324]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1298..1301] The) (JJ:[1302..1306] sole)
          (NN:[1307..1315] presence))
      (PP (IN:[1316..1318] of)
        (NP (NN:[1319..1324] K-ras) (NN:[1325..1333] mutation))))
    (VP (VBD:[1334..1337] was)
      (ADJP-PRD (JJ:[1338..1348] predictive)
        (PP (IN:[1349..1351] of)
          (NP (NN:[1353..1361] survival)))))
    (.:[1361..1362] .)))

;sentence 12 Span:1363..1537
;Additionally, when combined with elevated p21 or p185 expression in a  subset
;of patients with 4 or more years of follow-up, negative correlation with 
;survival was observed.
;[1405..1408]:gene-protein:"p21"
;[1412..1416]:gene-protein:"p185"
(SENT
  (S
    (ADVP (RB:[1363..1375] Additionally))
    (,:[1375..1376] ,)
    (SBAR
      (WHADVP-2 (WRB:[1377..1381] when))
      (S
        (NP-SBJ (-NONE-:[1381..1381] *))
        (VP (VBN:[1382..1390] combined)
          (PP-CLR (IN:[1391..1395] with)
            (NP
              (ADJP (VBN:[1396..1404] elevated))
              (NML
                (NML (NN:[1405..1408] p21)
                  (NML-1 (-NONE-:[1408..1408] *P*)))
                (CC:[1409..1411] or)
                (NML (NN:[1412..1416] p185)
                  (NML-1 (NN:[1417..1427] expression))))))
          (PP (IN:[1428..1430] in)
            (NP
              (NP (DT:[1431..1432] a) (NN:[1434..1440] subset))
              (PP (IN:[1441..1443] of)
                (NP
                  (NP (NNS:[1444..1452] patients))
                  (PP (IN:[1453..1457] with)
                    (NP
                      (NP
                        (QP (CD:[1458..1459] 4) (CC:[1460..1462] or)
                            (JJR:[1463..1467] more))
                        (NNS:[1468..1473] years))
                      (PP (IN:[1474..1476] of)
                        (NP (VB:[1477..1483] follow) (HYPH:[1483..1484] -)
                            (RP:[1484..1486] up)))))))))
          (ADVP-TMP-2 (-NONE-:[1486..1486] *T*)))))
    (,:[1486..1487] ,)
    (NP-SBJ-3
      (NP (JJ:[1488..1496] negative) (NN:[1497..1508] correlation))
      (PP (IN:[1509..1513] with)
        (NP (NN:[1515..1523] survival))))
    (VP (VBD:[1524..1527] was)
      (VP (VBN:[1528..1536] observed)
        (NP-3 (-NONE-:[1536..1536] *))))
    (.:[1536..1537] .)))

;section 13 Span:1541..1585
;PMID: 9537203 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1541..1545] PMID) (::[1545..1546] :) (CD:[1547..1554] 9537203)
        (NN:[1555..1556] -LSB-) (NNP:[1556..1562] PubMed) (::[1563..1564] -)
        (NN:[1565..1572] indexed) (IN:[1573..1576] for)
        (NNP:[1577..1585] MEDLINE-RSB-)))
